Single-isomer levalbuterol: A review of the acute data

Current Allergy and Asthma Reports

Volumn 3, Issue 2, 2003, Pages 172-178

  Nowak, Richard ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; IPRATROPIUM BROMIDE; ISOPRENALINE; LEVALBUTEROL; METHACHOLINE; ORCIPRENALINE; OXYGEN; PROPRANOLOL; SALBUTAMOL; BRONCHODILATING AGENT;

AREA UNDER THE CURVE; ASTHMA; BETA ADRENERGIC STIMULATION; BRONCHODILATATION; BRONCHODILATING ACTIVITY; CLINICAL TRIAL; COST OF ILLNESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SCREENING; EMERGENCY WARD; HEALTH PRACTITIONER; HOSPITAL ADMISSION; HUMAN; IN VITRO STUDY; INFLAMMATION; ISOMERISM; METERED DOSE INHALER; RACEMIC MIXTURE; REVIEW; SIDE EFFECT; ACUTE DISEASE; COMPARATIVE STUDY; ECONOMICS;

ACUTE DISEASE; ALBUTEROL; ASTHMA; BRONCHODILATOR AGENTS; HUMANS;

EID: 0038543534     PISSN: 15297322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11882-003-0031-8     Document Type: Review

References (52)

1. Bullowa J, Kaplan D: On the hyperdermic use of adrenalin chloride in the treatment of asthmatic attacks. Med News 1903:63-66.
2. Sly RM: New guidelines for diagnosis and management of asthma. Ann Allergy 1997, 78:427-437.
3. Nelson HS: b-adrenergic bronchodilators. N Engl J Med 1995, 333:499-506.
4. McCarren M, Zalenski R, McDermott M, Kaur K: Predicting recovery from acute asthma in an emergency diagnostic and treatment unit. Acad Emerg Med 2000, 7:28-35.
5. Ducharme F, Kramer M: Relapse following emergency treatment for acute asthma: Can it be predicted or prevented? J Clin Epidemiol 1993, 46:1395-1402.
6. Newcomb R, Akhter J: Outcomes of emergency room visits for asthma. I. Patient determinants. J Allergy Clin Immunol 1986, 77:309-315.
7. Emerman C, Woodruff P, Cydulka R, et al.: Prospective multicenter study of relapse following treatment for acute asthma among adults presenting to the ED. MARC investigators. Multicenter Asthma Research Collaboration. Chest 1999, 115:919-927.
8. Emerman C: Relapse following treatment of acute asthma in the ED. J Asthma 2000, 37:701-708.
9. Hartley D, Middlemiss D: Absolute configuration of the optical isomers of salbutamol. J Med Chem 1971, 14: 95-899.
10. Lotvall J, Palmqvist M, Arvidsson P, et al.: The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients. J Allergy Clin Immunol 2001, 108: 26-731.
11. Frieri M: Clinical and basic science research on allergic rhinitis and asthma from Nassau University Medical Center. Allergy Asthma Proc 2001, 22:162-172.
12. Cho S, Hartleroad J, Oh C: (S)-albuterol increases the production of histamine and IL-4 in mast cells. Int Arch Allergy Immunol 2001, 124:478-484.
13. Mitra S, Ugur M, Ugur O, et al.: (S)-albuterol increases intracellular free calcium by muscarinic receptor activation and a phospholipase C-dependent mechanism in airway smooth muscle. Mol Pharmacol 1998, 53:347-354.
14. Templeton A, Chapman I, Chilvers E, et al.: Effects of S-salbutamol on isolated human bronchus. Pulm Pharmacol Ther 1998:1-6.
15. Yamaguchi H, McCullough JR: S-albuterol exacerbates calcium responses to carbachol in airway smooth muscle cells. J Allergy Clin Immunol 1996, 14:47-55.
16. Nelson H, Bensch G, Pleskow W, et al.: improved bronchodilation with levalbuterol compared to racemic albuterol in patients with asthma. J Allergy Clin Immunol 1998, 102: 43-952.
17. Milgrom H, Skoner D, Bensch G, et al.: Low-dose levalbuterol in children with asthma: safety and efficacy compared with placebo and racemic albuterol. J Allergy Clin Immunol 2001, 108:938-945.
18. Gawchik S, Saccar C, Noonan M, et al.: The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients. J Allergy Clin Immunol 1999, 103:615-621.
19. Penn R, Frielle T, McCullough J, et al.: Comparison of R-, S, and RS-albuterol interaction with human b1- and b2-adrenergic receptors. Clin Rev Allergy Immunol 1996, 14:37-45.
20. Qureshi F, Pestian J, Davis P, Zaritsky A: Effect on nebulized ipratropium bromide on the hospitalization rates of children with asthma. N Engl J Med 1998, 339:1030-1035.
21. Lin R, Pesola G, Bakalchuk L, et al.: Superiority of ipratropium plus albuterol over albuterol alone in the emergency department management of adult asthma: a randomized clinical trial. Ann Emerg Med 1998, 21:208-213.
22. Munoz N, Vita A, Neeley S, et al.: Beta adrenergic modulation of formyl-methionine-leucine-phenylalanine-stimulated secretion of eosinophil peroxidase and leukotriene C4. J Pharmacol Exper Ther 1994, 268:139-143.
23. Barnes P: Effect of b-agonists on inflammatory cells. J Allergy Clin Immunol 1999, 104:S10-S17.
24. Leff AR, Herrnreiter A, Naclerio RM, et al.: Effect of enantiomeric forms of albuterol on stimulated secretion of granular protein from human eosinophils. Pulm Pharmacol Ther 1997, 10: 7-104.
25. Volchek G, Gleich G, Kita H: Pro- and anti-inflammatory effects of beta adrenergic agonists on eosinophil response to IL-5 [abstract]. J Allergy Clin Immunol 1998, 101 (suppl ):S35.
26. Ramsay C, Cowan J, Flannery E, et al.: Bronchoprotective and bronchodilator effects of single doses of (S)-salbutamol, (R)-salbutamol and racemic salbutamol in patients with bronchial asthma. Eur J Clin Pharmacol 1999, 55:353-359.
27. Perrin-Fayolle M: Salbutamol in the treatment of asthma [letter]. Lancet 1995, 346:1101.
28. Cockcroft DW, Swystun VA: Effect of single doses of S-salbutamol, R-salbutamol, racemic salbutamol, and placebo on the airway response to methacholine. Thorax 1997, 52:845-848.
29. Gumbhir-Shah K, Kellerman D, DeGraw S, et al.: Pharmacokinetics and pharmacodynamics of cumulative single doses of inhaled salbutamol enantiomers in asthmatic subjects. Pulm Pharmacol Ther 1999, 12:353-362.
30. Gumbhir-Shah K, Kellerman D, DeGraw S, et al.: Pharmacokinetic and pharmacodynamic characteristics and safety of inhaled albuterol enantiomers in healthy volunteers. J Clin Pharmacol 1998, 38:1096-1106.
31. Eaton E, Walle U, Wilson H, et al.: Stereoselective sulfate conjugation of salbutamol by human lung and bronchial epithelial cells. Br J Clin. Pharmacol 1996, 41:201-206.
32. Walle T, Eaton E, Walle U, Pesola G: Stereoselective metabolism of RS-albuterol in humans. Clin Rev Allergy Immunol 1996, 14:101-113.
33. Boulton D, Fawcett J: Enantioselective disposition of albuterol in humans. Clin Rev Allergy Immunol 1996, 14: 15-138.
34. Boulton DW, Fawcett JP: Pharmacokinetics and pharmacodynamics of single oral doses of albuterol and its enantiomers in humans. Clin Pharmacol Ther 1997, 62:138-144.
35. Lipworth BJ, Clark DJ, Koch P, Arbeeny C: Pharmacokinetics and extrapulmonary b2 adrenoceptor activity of nebulised racemic salbutamol and its R and S isomers in healthy volunteers. Thorax 1997, 52:849-852.
36. Dhand R, Goode M, Reid R, et al.: Preferential pulmonary retention of (S)-albuterol after inhalation of racemic albuterol. Am J Respir Crit Care Med 1999, 160:1136-1141.
37. Haider D: Levalbuterol affords superior health and cost benefit over racemic albuterol in the emergency department [abstract]. Respir Care 2001, 46:1081.
38. Nowak R, Emerman C: Levalbuterol is effective in acute asthma [abstractl. Am J Respir Crit Care Med 2001, 163 (suppl):A590.
39. Truitt T, Witko J, Halpern M: Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with chronic obstructive pulmonary disease or asthma. Chest 2003, 123(In press).
40. Carl J, Myers T, Kercsmar C: Comparison of levalbuterol and racemic albuterol for treatment of acute asthma in pediatric patients [abstract]. Chest 2001, 120:137S.
41. Emerman C, Nowak R: Inverse correlations between (S)-albuterol levels and FEV1 in the emergency department [abstract]. Acad Emerg Med 2002, 9:404.
42. McDowell K, Chatburn R, Myers T, et al.: A cost-saving algorithm for children hospitalized for status asthmaticus. Arch Pediatr Adolesc Med 1998, 152:977-984.
43. Asmus M, Hendeles L: Levalbuterol nebulizer solution: Is it worth five times the cost of albuterol? Pharmacotherapy 2000, 20:123-129.
44. Ahrens R, Weinberger M: Levalbuterol and racemic albuterol: Are there therapeutic differences? J Allergy Clin Immunol 2001, 108:681-684.
45. Lewis M, Harris S, Campbell S, et al.: Improving resource utilization with new technologies [abstract]. Respir Care 2000, 45:981.
46. Pikarsky R, Acevedo R: Clinical and economic impact resulting from a hospital-wide conversion from racemic albuterol to levalbuterol [abstract]. Chest 2002, 122:25S.
47. Pikarsky R, Acevedo R, Roman C, Farrell T: Comparison in rates of breakthrough treatments during a conversion from racemic albuterol to levalbuterol [abstract]. Chest 2002, 122: 46S.
48. Truitt T, Witko J, Kotter S, Gordon I: Levalbuterol reduces total and breakthrough treatments in hospitalized patients. Am J Respir Crit Care Med 2000, 161:A553.
49. Asmus M, Hendeles L, Weinberger M, et al.: Levalbuterol has not been established to have therapeutic advantage over racemic albuterol [letter]. J Allergy Clin Immunol 2002, 110: 25.
50. Chowdhury B: Comparative efficacy of levalbuterol and racemic albuterol in the treatment of asthma [letter]. J Allergy Clin Immunol 2002, 110:324.
51. Milgrom H, Skoner D, Bensch G, et al.: Reply. J Allergy Clin Immunol 2002, 110:325-328.
52. Schreck D, Brotea C, Shah S: Comparison of racemic albuterol and levalbuterol in the treatment of acute asthma [abstract]. Ann Emerg Med 2001, 38:S10.